Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 5/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 4/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9276917 | 1.00 | FPR2 (0.50) | FPR2ATMCTSKELANEAAK1 | |
| SCHEMBL7414757 | 0.88 | ATM (0.58) | FPR2ATMCTSKELANEAAK1 | |
| SCHEMBL7413361 | 0.86 | ATM (0.43) | ATMCTSKELANEAAK1 | |
| SCHEMBL7466082 | 0.85 | AAK1 (0.61) | ATMCTSKAAK1CTSSCTSL | |
| SCHEMBL14923445 | 0.85 | AAK1 (0.61) | ATMCTSKAAK1CTSSCTSL | |
| SCHEMBL7466643 | 0.85 | AAK1 (0.61) | ATMCTSKAAK1CTSSCTSL | |
| SCHEMBL8880230 | 0.85 | ATM (0.46) | ATMCTSKELANEAAK1CTSS | |
| SCHEMBL7421358 | 0.83 | FPR2 (0.51) | FPR2ATMCTSKAAK1CTSS | |
| SCHEMBL3346730 | 0.82 | TACR1 (0.53) | ATMCTSKAAK1CTSSCTSL | |
| SCHEMBL7417030 | 0.82 | TACR1 (0.53) | ATMCTSKAAK1CTSSCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2019-06-06 | — | — | US | disclosed |
| US-5733882-A | Retroviral protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1998-03-31 | — | — | US | disclosed |
| EP-0602069-A4 | RETROVIRAL PROTEASE INHIBITORS. | SMITHKLINE BEECHAM CORP (US) | 1995-05-03 | — | — | EP | disclosed |
| EP-0602069-A1 | RETROVIRAL PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-06-22 | — | — | EP | disclosed |
| WO-1993002057-A1 | RETROVIRAL PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169181-A1 | FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, DNPEP, FOLH1 | FPR2 499/4885ATM 1810/4885CTSK 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.